Drug Database
TR

treprostinil

✓ Approved

United Therapeutics · PTGIR · 小分子

什么是 treprostinil?

treprostinil 是一种小分子,由United Therapeutics研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

公司United Therapeutics
药物类别小分子
分子靶点PTGIR
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

treprostinil 作用于 1 个分子靶点:

PTGIRprostaglandin I2 receptor (IP, PRIPR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

treprostinil 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersPulmonary hypertension✓ Approved

相关研究文献

PubMedPharmacotherapy2026-11-19

Selexipag as a Therapeutic Alternative for Treprostinil-Induced Thrombocytopenia in Pulmonary Arterial Hypertension: A Case Report.

Kido Kazuhiko K, Madgula Anantha A, Coons James C JC, Caccamo Marco M et al.

Parenteral prostacyclin pathway agent-induced thrombocytopenia may require dose reduction or therapy discontinuation to mitigate the adverse events. However, the pulmonary arterial hypertension (PAH) guidelines do not suggest any strategy to overcome treprostinil-induced thrombocytopenia. Selexipag is an oral, non-prostanoid, selective IP receptor agonist. This is the first case report proposing the use of selexipag, due to its minimal thrombocytopenia risk, when severe treprostinil-induced thrombocytopenia occurs in practice. A 66-year-old woman presented to the hospital with new-onset PAH and right ventricular dysfunction. Due to the high mortality risk, the patient was initially started on intravenous treprostinil. The clinical course was complicated by probable treprostinil-induced thrombocytopenia. Due to the need for prostacyclin pathway therapy, the decision was made to switch from intravenous treprostinil to oral selexipag. The nadir platelet count was 30,000/μL. Approximately 72 h after discontinuation of treprostinil and maintaining selexipag 1600 mcg twice daily, the platelet count improved to 46,000/μL on the day of discharge. Several days after discharge, the platelet count further improved to 55,000/μL. The repeated platelet count 1 month after discharge normalized to 329,000/μL. Our case report described the successful use of selexipag to overcome treprostinil-induced thrombocytopenia, owing to its limited effect on platelet aggregation.

PMID 43053638
阅读全文 →
PubMedCJC open2026-11-17

Transition From Continuous Intravenous to Inhaled Treprostinil: A Case of Refractory Pulmonary Arterial Hypertension With Catheter-related Infection.

Yamanaka Shun S, Hiraide Takahiro T, Momoi Mizuki M, Seki Yurina Y et al.

PMID 43041987
阅读全文 →
PubMedMed (New York, N.Y.)2026-11-14

Idiopathic pulmonary fibrosis: Five trials to watch.

Koudstaal Thomas T, Verwaerde Stijn S, Moor Catharina C CC, Wijsenbeek Marlies S MS

For a decade, treatment of idiopathic pulmonary fibrosis (IPF) relied on two antifibrotic drugs that slow down lung function decline. Positive phase 3 trials for nerandomilast and inhaled treprostinil are now changing this landscape. Additionally, new therapies are in mid- and late-stage clinical development, each targeting fibrosis in a different way. In this Trial Watch, we focus on five of these emerging approaches.

PMID 43025400
阅读全文 →
PubMedInternational journal of molecular sciences2026-11-14

Emerging Therapies in Pulmonary Fibrosis: A Common Pathway for the Action of Diverse Pharmacologic Agents.

Bolger Graeme B GB

Fibrotic lung diseases are a heterogeneous set of disorders characterized by progressive infiltration of the pulmonary interstitium by inflammatory cells and fibroblasts, leading to destruction of normal pulmonary tissue and increased extracellular matrix deposition. Fibrotic lung disease can be initiated by numerous triggers-genetic, immunologic, pharmacologic, environmental, infectious-that share many downstream effectors, leading to injury patterns with substantial pathologic and clinical overlap. Recent preclinical studies have expanded our knowledge of the mechanisms of lung inflammation and implicated the key role of specific cytokines in the pathogenesis of lung inflammation. They reinforce the concept that inflammation is a key precursor of lung fibrosis. They have also identified specific intracellular signaling pathways that are modulated, at least in part, by cytokine signaling and that have been shown to be emerging targets for drugs that target inflammation in the lung. Recent advances in therapeutics have yielded two new drugs active in pulmonary fibrosis, the PDE4-selective inhibitor nerandomilast and the prostacyclin analog treprostinil. There is now compelling evidence that, despite their structural differences, these two drugs act through a common mechanism, the cAMP signaling pathway. The new clinical trial results have provided critical confirmation that these targets are indeed key regulators of lung fibrosis and inflammation and, in turn, have provided well-validated clinical evidence that these agents have therapeutic value in patients.

PMID 43028022
阅读全文 →
PubMedFrontiers in pharmacology2026-11-10

Tacrolimus ameliorates pulmonary hypertension associated with pulmonary fibrosis via modulation of vascular remodeling.

Liu Xueze X, Chen Qi Q, Hu Yayue Y, Liu Zhigang Z et al.

Idiopathic pulmonary fibrosis (IPF) is frequently complicated by pulmonary hypertension (IPF-PH), a severe condition that worsens symptoms, reduces exercise capacity, and shortens survival. Current anti-fibrotic and PH-targeted therapies show limited efficacy in IPF-PH, and the therapeutic role of tacrolimus in this composite disease remains underexplored. A bleomycin-induced IPF-PH rat model was established. Rats were randomized into control, bleomycin model, treprostinil (positive control), and tacrolimus (0.05 mg/kg/day, subcutaneous, 21 days) groups. Right ventricular systolic pressure (RVSP), echocardiography, right ventricular and lung histology, immunohistochemistry, qRT-PCR, and Western blot were assessed. In vitro, C166 endothelial cells and primary rat pulmonary arterial endothelial cells were stimulated with bleomycin with or without tacrolimus; MOVAS smooth muscle cells were stimulated with TGF-β1 with or without tacrolimus. Endpoints included cell viability, tube formation, ROS, SOD/GSH, apoptosis, proliferation/migration, and MAPK/PI3K/AKT signaling. Tacrolimus reduced RVSP, improved PAT/PET and right heart function, attenuated right ventricular hypertrophy and pulmonary fibrosis, and decreased vascular wall thickness and α-SMA expression. It also downregulated fibrosis markers Fn1 and Col1a1. In endothelial cells, tacrolimus restored P-VEGFR2/VEGFR2 and VE-cadherin expression, promoted tube formation, reduced apoptosis (Bax/Bcl-2, cleaved caspase-9/3), and alleviated oxidative stress (ROS, SOD/GSH, Keap1/HO-1). In smooth muscle cells, tacrolimus inhibited TGF-β1-induced proliferation and migration and reduced Ki67 expression. Mechanistically, tacrolimus suppressed MAPK (JNK, ERK, p38) and PI3K/AKT pathway activation in vivo and in vitro. Tacrolimus ameliorates bleomycin-induced IPF-PH through vascular remodeling-oriented, multi-target effects, including endothelial protection, suppression of oxidative stress and apoptosis, and inhibition of smooth muscle proliferation, partly via MAPK and PI3K/AKT signaling. These findings support tacrolimus as a potential therapeutic candidate for IPF-PH, especially in patients with prominent vascular remodeling, while highlighting the need for further dose-response, target-specific, immunomodulatory, and delivery optimization studies before clinical translation.

PMID 43005107
阅读全文 →
PubMedExpert opinion on pharmacotherapy2026-11-09

Contemporary pharmacotherapeutic options for chronic thromboembolic pulmonary hypertension.

Diao Jia-Kang JK, Lin Jun-Le JL, Liu Chao C, Jing Zhi-Cheng ZC

Chronic thromboembolic pulmonary hypertension (CTEPH) is driven by both proximal thromboembolic obstruction and microvasculopathy. While pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) are effective for selected patients, pharmacotherapy is indispensable in the contemporary era. This review provides an updated overview of medical therapy within a multimodal treatment paradigm. This review examines lifelong anticoagulation, including comparative evidence for vitamin K antagonists and direct oral anticoagulants, and the efficacy and safety of approved and off-label PH-targeted therapies for inoperable CTEPH or persistent/recurrent PH after PEA. Riociguat, phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, treprostinil, and selexipag are reviewed, together with combination therapy, pharmacotherapy before and after PEA or BPA, and assessment of treatment response. Riociguat has the strongest evidence for symptomatic inoperable CTEPH or persistent/recurrent PH after PEA; subcutaneous treprostinil may benefit selected patients with severe disease. PH-targeted therapy should not delay PEA referral. Anatomical inoperability, procedural risk, limited specialist access, and informed refusal require different responses. After intervention, decisions to continue medication should consider residual disease, symptoms, right ventricular function, and exercise limitation, not resting hemodynamics alone. Comparative studies should determine who benefits from medication before BPA and when it can safely be withdrawn.

PMID 43001523
阅读全文 →

注册免费账户还可查看另外 925 篇文献

免费注册查看全部文献 →

了解更多treprostinil